Genmab's blockbuster Darzalex surpasses $2B in sales

Genmab A/S (CSE:GEN; Pink:GMXAY) said sales of its multiple myeloma drug Darzalex daratumumab reached $2 billion in 2018, triggering a $75 million milestone payment from partner Janssen Biotech Inc.

Last February, Genmab projected that 2018 Darzalex sales would surpass $2 billion (see “Darzalex Guidance Buoys Genmab Shares”)...